IROs at biotech and pharmaceutical companies get some food for thought
The biotechnology and pharmaceutical industries have been the most fashionable sectors of the past couple of years. The market has this idea that, much like technology companies in the late 1990s, any biotech or pharma company could be the next one to skyrocket. If it discovered a cure for cancer or Aids, for example, the stock price of one of these companies would soar. The problem, however, is that retail investors’ lack of knowledge of the nuances of these complicated industries is
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495
